Bradmer announces additions to Scientific Advi...( TSX...),Health

TSX: BMR

TORONTO, Dec. 12 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that Keith L. Black, M.D. and Roger Stupp, M.D. have agreed to join the Company's Scientific Advisory Board. Dr. Black is one of the leading neuro-oncology surgeons in North America, having performed more than 5,000 operations for the resection of brain tumors, the preliminary step in the standard of care of primary glioblastoma multiforme, Bradmer's lead indication. Dr. Stupp's leadership role in European and international cancer research is exemplified by his appointment as the Chairman of the Clinical Research Division of the European Organisation for Research and Treatment of Cancer (EORTC), and his role as lead investigator for numerous international trials in glioblastoma multiforme.

"Dr. Black and Dr. Stupp's renowned clinical and research skills in the study of brain cancer will provide a tremendous contribution to our Scientific Advisory Board. Their active patient practice and frontline experience in the treatment of glioblastoma multiforme will benefit our entire team at Bradmer," said Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer.

"With the addition of Drs. Black and Stupp and the continued involvement of Drs. Bigner and Zalutsky, we have secured the involvement of the preeminent thought leaders in the study of glioblastoma multiforme from the leading brain cancer centers in North America and Europe," added Donald W. Kufe, M.D., Chairman of Bradmer's Scientific Advisory Board.

Dr. Black is currently the Chairman of the Department of Neurosurgery as well as the Director of the Comprehensive Brain Tumor Program at Cedars-Sinai Medical Center in Los Angeles, California. He also serves as the Director of the Maxine Dunitz Neurosurgical Institute and holds the Ruth and Lawrence
'/>"/>